World Investment Advisors Acquires 2,109 Shares of Elevance Health, Inc. $ELV

World Investment Advisors increased its stake in Elevance Health, Inc. (NYSE:ELV) by 7.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 30,399 shares of the company’s stock after buying an additional 2,109 shares during the quarter. World Investment Advisors’ holdings in Elevance Health were worth $8,899,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ELV. Murphy Middleton Hinkle & Parker Inc. purchased a new stake in Elevance Health in the fourth quarter worth $5,941,000. Bright Rock Capital Management LLC purchased a new position in shares of Elevance Health during the 4th quarter valued at $7,362,000. Prana Capital Management LP grew its stake in shares of Elevance Health by 798.9% during the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock worth $16,684,000 after acquiring an additional 45,889 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Elevance Health during the 3rd quarter worth $10,047,000. Finally, Loews Corp increased its holdings in Elevance Health by 107.5% in the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock worth $35,543,000 after acquiring an additional 57,000 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

ELV has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. UBS Group increased their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Guggenheim lifted their target price on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Morgan Stanley boosted their price target on shares of Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Finally, Robert W. Baird upped their price target on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $419.16.

Insiders Place Their Bets

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

Shares of ELV opened at $416.97 on Friday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $427.19. The stock’s 50-day simple moving average is $391.29 and its 200 day simple moving average is $351.14. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market capitalization of $90.55 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the previous year, the firm earned $11.97 EPS. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts forecast that Elevance Health, Inc. will post 26.86 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were paid a dividend of $1.72 per share. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s payout ratio is currently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.